Dong‐Wook Kim - Concepedia

Author

Dong‐Wook Kim

Also Known As

Chang-Ki Min, Chang‐Ki Min, Charles Chuah, D.-W Kim, DONG-WOOK KIM, Dae Jin Cho, Dae-Young Zang, Daniela S. Krause, Dong-Wook Kim, Dong-wook Kim

599

Publications

20K

Citations

H-Index

180

Concepts

All Affiliations

Catholic University of Korea The Catholic University of Korea Seoul St. Mary's Hospital The University of Texas MD Anderson Cancer Center Jena University Hospital Charité - Universitätsmedizin Berlin

About

Dong‐Wook Kim is an author at Catholic University of Korea specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	81	3.1K
2	Health Sciences	19	34	1.2K
3	Public Health	3	3	162
4	Natural Sciences	2	2	28
5	Engineering	1	1	96

Dong‐Wook Kim

212

Publications

18K

Citations

H-Index

Page 1

	Year	Citations
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil, New England Journal of Medicine	2010	1.7K
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Blood	2011	601
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Blood	2018	572
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim, Journal of Clinical Oncology	2008	487
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Journal of Clinical Oncology	2017	480
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial Jörge E. Cortes, Dong‐Wook Kim, Hagop M. Kantarjian, Journal of Clinical Oncology	2012	465
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Blood	2011	457
PKC-θ knockout mice are protected from fat-induced insulin resistance Jason K. Kim, Jonathan J. Fillmore, Mary Jean Sunshine, Journal of Clinical Investigation	2004	454
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, New England Journal of Medicine	2019	449
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon, JNCI Journal of the National Cancer Institute	2011	424

Page 1